ConductScience.org, home

Paper24065243

Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.

Copelan EA and 37 others. Blood, 2013. Cited by 143 papers, by iCite.

Cite this record

ConductScience Library. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Papers, record 24065243. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24065243

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.
PubMed
Journal
Blood
PubMed
Year
2013
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
143
iCite
Relative citation ratio, by iCite
4.79
iCite
Revised in PubMed
2024-02-23
PubMed

Authors38

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Copelan EAEdward A
2Hamilton BKBetty K
3Avalos BBelinda
4Ahn KWKwang Woo
5Bolwell BJBrian J
6Zhu XXiaochun
7Aljurf MMahmoud
8van Besien KKoen
9Bredeson CChristopher
10Cahn JYJean-Yves
11Costa LJLuciano J
12de Lima MMarcos
13Gale RPRobert Peter
14Hale GAGregory A
15Halter JJoerg
16Hamadani MMehdi
17Inamoto YYoshihiro
18Kamble RTRammurti T
19Litzow MRMark R
20Loren AWAlison W

Source PubMed

See all 38 authorsDownload CSV of authors

Topics25

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Hematopoietic Stem Cell TransplantationMajor topic
Leukemia, MyeloidMajor topic
Whole-Body IrradiationMajor topic
Acute Disease
Adolescent
Adult
Busulfan
Child
Child, Preschool
Combined Modality Therapy
Cyclophosphamide
Disease-Free Survival
Female
Humans
Male
Middle Aged
Multivariate Analysis
Remission Induction
Siblings
Time Factors
Transplantation, Homologous
Treatment Outcome
Unrelated Donors
Young Adult

Source PubMed

Download CSV of topics

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
T32 HL007899NHLBI NIH HHSUnited StatesT32HL007899PubMedNIH RePORTER
U01 HL069294NHLBI NIH HHSUnited StatesU01HL069294PubMed and NIHNIH RePORTER
U24 CA076518NCI NIH HHSUnited StatesU24CA076518PubMedNIH RePORTER
5U01HL069294NHLBI NIH HHSUnited StatesU01HL069294PubMed and NIHNIH RePORTER

Download CSV of grants

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in24311716Busulfan or TBI: answer to an age-old question.https://conductscience.org/library/papers/24311716

Source PubMed

Download CSV of comments and corrections

References47

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
110090927
Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group.
Blood1999https://conductscience.org/library/papers/10090927PubMed
210800057The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.Bone Marrow Transplant2000https://conductscience.org/library/papers/10800057PubMed
3381925Marrow transplantation for acute nonlymphoblastic leukemia in first remission.N Engl J Med1979https://conductscience.org/library/papers/381925PubMed
415126320The impact of low-dose busulfan on clonal dynamics in nonhuman primates.Blood2004https://conductscience.org/library/papers/15126320PubMed
511939604Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study.Biol Blood Marrow Transplant2002https://conductscience.org/library/papers/11939604PubMed
67050046Marrow transplantation for acute nonlymphoblastic leukemic in first remission using fractionated or single-dose irradiation.Int J Radiat Oncol Biol Phys1982https://conductscience.org/library/papers/7050046PubMed
715166618Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy.Anticancer Drugs2004https://conductscience.org/library/papers/15166618PubMed
818690856Busulphan in blood and marrow transplantation: dose, route, frequency and role of therapeutic drug monitoring.Curr Clin Pharmacol2007https://conductscience.org/library/papers/18690856PubMed
98167351A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group.Blood1994https://conductscience.org/library/papers/8167351PubMed
107917905Relationships between ablation of distinct haematopoietic cell subsets and the development of donor bone marrow engraftment following recipient pretreatment with different alkylating drugs.Br J Cancer1994https://conductscience.org/library/papers/7917905PubMed
112591002Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation.Cancer Chemother Pharmacol1989https://conductscience.org/library/papers/2591002PubMed
121586710
Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse.
Blood1992https://conductscience.org/library/papers/1586710PubMed
137825973Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: rationale and pitfalls (review).Anticancer Res1994https://conductscience.org/library/papers/7825973PubMed
141859895Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2.Blood1991https://conductscience.org/library/papers/1859895PubMed
1516641398Hematopoietic stem-cell transplantation.N Engl J Med2006https://conductscience.org/library/papers/16641398PubMed
162224134Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens.Blood1990https://conductscience.org/library/papers/2224134PubMed
1712149198Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome.Blood2002https://conductscience.org/library/papers/12149198PubMed
1812374454
Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality.
Biol Blood Marrow Transplant2002https://conductscience.org/library/papers/12374454PubMed
196996481Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.Am J Med1980https://conductscience.org/library/papers/6996481PubMed
208201385
Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle.
J Clin Oncol1994https://conductscience.org/library/papers/8201385PubMed

See all 47 referencesDownload CSV of references

Cited by80

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 143 citations.

PMIDTitleJournalYearIn PapersSource
42819397The complications of irradiation or busulfan for CAYA before hematopoietic stem cell transplantation: a systematic review and meta-analysis.Front Pediatr2026https://conductscience.org/library/papers/42819397PubMed
42477157
Allogeneic hematopoietic cell transplantation from haploidentical donors with total body irradiation versus chemo-based regimens for adult AML patients in first complete remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Bone Marrow Transplant2026https://conductscience.org/library/papers/42477157PubMed
42469396
Impact of conditioning regimen on outcomes of young AML patients ( < 40 years) undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation.
Bone Marrow Transplant2026https://conductscience.org/library/papers/42469396PubMed
41949966[Allogeneic hematopoietic stem cell transplantation in children's acute myeloblastic leukemia: Survival and relapse].Tunis Med2025https://conductscience.org/library/papers/41949966PubMed
41730941Busulfan resistance in AML is associated with changes in mitochondrial copy number and lipid metabolism.Sci Rep2026https://conductscience.org/library/papers/41730941PubMed
41152589Comparison of outcomes of BuCy versus BuCyMel as preparation for allogeneic HSCT in infants with acute myeloid leukemia in first complete remission: a multicenter study from the EBMT PDWP.Bone Marrow Transplant2026https://conductscience.org/library/papers/41152589PubMed
40514011Seizure Prophylaxis and its Impact on Busulfan Pharmacokinetics and Dosing in a Novel Timed Sequential Protocol: MD Anderson Experience.Transplant Cell Ther2025https://conductscience.org/library/papers/40514011PubMed
40255903
Optimizing treatment efficacy and fertility preservation in patients undergoing hematopoietic stem cell transplantation: A narrative review of ovarian shielding with total-body irradiation or treosulfan-based conditioning regimens.
Reprod Med Biol2025https://conductscience.org/library/papers/40255903PubMed
39168989Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial.Blood Cancer J2024https://conductscience.org/library/papers/39168989PubMed
38702400Comparable outcomes for TBI-based versus treosulfan based conditioning prior to allogeneic hematopoietic stem cell transplantation in AML and MDS patients.Bone Marrow Transplant2024https://conductscience.org/library/papers/38702400PubMed
38651157Clinical efficacy and safety of combined anti-BCMA and anti-CD19 CAR-T cell therapy for relapsed/refractory multiple myeloma: a systematic review and meta-analysis.Front Oncol2024https://conductscience.org/library/papers/38651157PubMed
38438648
Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell transplantation in measurable residual disease-negative CR1.
Bone Marrow Transplant2024https://conductscience.org/library/papers/38438648PubMed
37627199Risk-Stratified Therapy for Pediatric Acute Myeloid Leukemia.Cancers (Basel)2023https://conductscience.org/library/papers/37627199PubMed
37491812
Saliva as a noninvasive sampling matrix for therapeutic drug monitoring of intravenous busulfan in Chinese patients undergoing hematopoietic stem cell transplantation: A prospective population pharmacokinetic and simulation study.
CPT Pharmacometrics Syst Pharmacol2023https://conductscience.org/library/papers/37491812PubMed
37283891Influence of SPIO labelling on the function of BMSCs in chemokine receptors expression and chemotaxis.PeerJ2023https://conductscience.org/library/papers/37283891PubMed
36966213Intravenous Busulfan, Dimethylacetamide and neurotoxicity after high-dose pretransplant conditioning chemotherapy.Bone Marrow Transplant2023https://conductscience.org/library/papers/36966213PubMed
36505853Conditioning regimens for allogeneic hematopoietic cell transplantation in acute myeloid leukemia: Real-world data from the Japanese registry studies.Front Oncol2022https://conductscience.org/library/papers/36505853PubMed
36357773
Myeloablative conditioning regimens in adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation in complete remission: a systematic review and network meta-analysis.
Bone Marrow Transplant2023https://conductscience.org/library/papers/36357773PubMed
35610308A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation.Bone Marrow Transplant2022https://conductscience.org/library/papers/35610308PubMed
35340233Two Different Transplant Preconditioning Regimens Combined with Irradiation and Chemotherapy in the Treatment of Childhood Leukemia: Systematic Review and Meta-Analysis.J Healthc Eng2022https://conductscience.org/library/papers/35340233PubMed

See all 80 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/24065243

GET https://conductscience.org/api/papers/v1/24065243/authors?page=2